Results 51 to 60 of about 581 (108)

Efficacy and safety of sonidegib combined with photodynamic therapy in basal cell carcinoma: A retrospective case series of 7 patients

Photodiagnosis and Photodynamic Therapy
Background: Management of basal cell carcinoma (BCC) in cosmetically critical facial areas remains challenging when surgery is contraindicated or declined.
Jiaxi Lai, Kaixin Li, Min Xu, Liyuan Zeng, Caiyan Li, Siqi Li, Li Zhong, Wei Liu, Xiaoshuang Liang, Jingwen Zou, Renliang He, Weiqin Shen, Min Li, Yongfeng Chen, Rongyi Chen   +14 more
doaj   +1 more source

A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low‐Risk Basal Cell Carcinoma

Experimental Dermatology, Volume 35, Issue 5, May 2026.
Neoadjuvant treatment with oral itraconazole for two months demonstrated significant responses in low‐risk basal cell carcinomas. This effect was associated with decreased tumour angiogenesis, presenting a favourable safety profile for patients. ABSTRACT Recently, new treatment strategies have been developed for advanced or metastatic basal cell ...
Rodrigo Pérez Pereira, Dienifer Hermann Sirena, Sérgio Jobim de Azevedo, Monique Maria Franco da Silva, Mariani Magnus da Luz Andrade, Charles Francisco Ferreira, Tiago Elias Heinen, Renato Marchiori Bakos   +7 more
wiley   +1 more source

Cancer‐Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities

Advanced Science, Volume 13, Issue 24, 27 April 2026.
ABSTRACT Cancer‐associated fibroblasts (CAFs) are the predominant stromal components within the tumor microenvironment (TME), playing multifaceted roles in cancer progression through dynamic interactions with neoplastic and immune cells. Emerging evidence has revealed remarkable heterogeneity and plasticity of CAFs, which originate from diverse ...
Rujiao Liu, Lili Su, Shuiping Gao, Wenting Liu, Hongxia Wang   +4 more
wiley   +1 more source

Metastatic Basal Cell Carcinoma With Unusual Molecular Genetics Findings

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Basal cell carcinoma (BCC) rarely metastasizes to other parts of the body. When metastasis occurs, it usually involves regional lymph nodes. BCC lesions located in the head and neck region have been shown to spread to cervical lymph nodes.
Noora Al‐Hail, Majid Al‐Abdulla, Syed Rizvi, Nazeeha Al‐Hayki   +3 more
wiley   +1 more source

Supplementary Table 1 from An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib

, 2016
functional resistance in vitro and SMO mutations found in study subjects. (a) SMO mutations with previously demonstrated functional resistance in vitro to Smoothened inhibitors, including vismodegib and sonidegib.
Anthony E. Oro (11457962), Kavita Y. Sarin (3605282), Anne Lynn S. Chang (3339900), Christina Danial (14998952)   +3 more
core   +1 more source

Successful Alternative Administration of Sonidegib in a Patient with Gorlin-Goltz Syndrome and Dysphagia: A Case Report

Case Reports in Dermatology
Introduction: Activation of the Hedgehog (HH) pathway is a key factor in the development of basal cell carcinoma. Case Presentation: Approved HH pathway inhibitors, like vismodegib and sonidegib, are supplied in capsule form.
Armin Bender, Lisa Krönig
doaj   +1 more source

Mohs Surgery Outcomes for Basal Cell Carcinoma Treated With Neoadjuvant Sonic Hedgehog Inhibitor

International Journal of Dermatology, Volume 65, Issue 7, Page 1493-1494, July 2026.
Ghassan Barnawi, Raquel Lazarowitz, Sarah Aly, Houriah Nukaly, Eduardo Weiss   +4 more
wiley   +1 more source

Pleural‐Based GLI1‐Altered Mesenchymal Tumor With ACTB‐GLI1 Fusion: A Rare Pulmonary Entity Mimicking Synovial Sarcoma

Thoracic Cancer, Volume 17, Issue 7, April 2026.
Pleural‐based GLI1‐altered mesenchymal tumor presenting as an incidental thoracic mass, characterized by biphasic morphology and ACTB‐GLI1 fusion, managed by thoracoscopic resection and surveillance. ABSTRACT GLI1‐altered mesenchymal tumors are exceptionally rare mesenchymal tumors, with recent molecular studies implicating GLI1 gene fusion or ...
Marco Lizwan, Li Xiao, Chun Yuen Chow, Hiu Yeung Lau, Boon‐Hean Ong   +4 more
wiley   +1 more source

Supplementary Figure 1 from A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

, 2014
PDF file - 29K, Chemical structures of sonidegib and cyclopamine.
Hussein A. Tawbi (14915835), Dereck D. Amakye (14987163), Jose Baselga (108032), Devalingam Mahalingam (4593907), Christian P. Turtschi (14990786), Yaping Shou (6472547), Kristine L. Rose (14987166), Lin Yang (45852), Ronald G. Stoller (14990783), John Sarantopoulos (4489537), Camille Granvil (14990792), Eunju Hurh (2686873), Anne L. Thomas (7163420), Reinhard Dummer (103718), Jordi Rodon (201558), Alain C. Mita (14976127), Melissa A. Moles (14990789)   +16 more
core   +1 more source

RNA‐Sequencing Reveals Two Subgroups of Eccrine Porocarcinomas and Poromas

Journal of Cellular and Molecular Medicine, Volume 30, Issue 8, April 2026.
ABSTRACT Eccrine porocarcinoma (EPC), a rare malignant eccrine gland tumour, remains molecularly understudied. Transcriptomic studies of EPC and benign eccrine poroma (EP) have identified recurrent fusions and expression changes, but differences distinguishing malignant EPC from benign EP are unclear.
Maya Puttonen, Sami Kilpinen, Maria von Willebrand, Kalle Ojala, Tom Böhling, Virve Koljonen, Harri Sihto   +6 more
wiley   +1 more source